CLINICAL TRIALS PROFILE FOR MIZORIBINE
✉ Email this page to a colleague
Clinical Trials for Mizoribine
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT02005757 ↗ | Efficacy and Safety Study of Mizoribine in Active Rheumatoid (AMOLED) | Unknown status | Chong Kun Dang Pharmaceutical | Phase 2 | The purpose of this study is to access the efficacy and safety of Mizoribine 150mg qid and 50mg tid in active rheumatoid arthritis patients unsuccessfully treated with disease-modifying antirheumatic drug. |
NCT02256150 ↗ | A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Lupus Nephritis | Completed | Asahi Kasei Pharma Corporation | Phase 3 | To demonstrate that the treatment effect in lupus nephritis of MZR is non-inferior to that of standard therapy CTX through analyzing overall remission rate after treatment. |
NCT02257697 ↗ | A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Refractory Nephrotic Syndrome | Completed | Asahi Kasei Pharma Corporation | Phase 3 | To demonstrate that the treatment effect in refractory nephrotic syndrome of MZR is non-inferior to that of standard therapy CTX through analyzing overall remission rate after treatment. |
NCT02373202 ↗ | A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis (SARIL-RA-HARUKA) | Completed | Regeneron Pharmaceuticals | Phase 3 | Primary Objective: To document the long-term safety of sarilumab added to non-methotrexate (non-MTX) disease-modifying antirheumatic drugs (DMARDs) or as monotherapy. Secondary Objective: To document the long term efficacy of sarilumab added to non-MTX DMARDs or as monotherapy. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Mizoribine
Condition Name
Clinical Trial Locations for Mizoribine
Clinical Trial Progress for Mizoribine
Clinical Trial Phase
Clinical Trial Sponsors for Mizoribine
Sponsor Name